Recruiting studies: Relapsed Refractory Autoimmune Diseases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07095075 A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597 Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Phase 1/Phase 2 · 10 location(s) · CRISPR Therapeutics AG · NCT07549698 Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096 Orelabrutinib in the Treatment of Relapsed/Refractory AIHA
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07453368 Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06428188 CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087 A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721 A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patient
EARLY_Phase 1 · 1 location(s) · Neukio Biotherapeutics (Shanghai) Co., Ltd. · NCT07144462 A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647 CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129 Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06946485 CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06680388 Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270 A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06653556 Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in
EARLY_Phase 1 · 1 location(s) · Tianjin Huanhu Hospital · NCT06939166 The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopeni
Phase 2 · 4 location(s) · Seoul National University Hospital · NCT05599880 Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · 2 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236801 Exploratory Clinical Study on the Safety of STR-P004
NA · 1 location(s) · Beijing GoBroad Hospital · NCT07143617 AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stud
Phase 2 · 52 location(s) · Artiva Biotherapeutics, Inc. · NCT06991114 RN1201 Injection in the Treatment of Antibody-Mediated Diseases
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07072247 A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflamm
Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07331272 Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT07148791 A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · CytoCares Inc · NCT07193810 An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT07174843 A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Phase 1 · 6 location(s) · Kite, A Gilead Company · NCT07304154 Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07032129 A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p
EARLY_Phase 1 · 2 location(s) · Grit Biotechnology · NCT07205315 Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous Sys
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT04561557 CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1/Phase 2 · 1 location(s) · Marcela V. Maus, M.D.,Ph.D. · NCT07388277

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.